NEWS
Unravelling the mysteries of cancer cells
Seahorse instrument helps researchers develop novel cell therapies.
Evaluerer Nye metoder: - Tar arbeidet på største alvor
Årets første møte i serien Fremtidens kreftbehandling ble avholdt digitalt onsdag 10. februar.
Mer presis behandling kan redde liv
Vårt mål er at nye kreftbehandlinger i samarbeid skal utvikles på 5 istedenfor 10 år.
Hemispherian reaches new milestone
Hemispherian closed successful seed financing round
First pharma company joins IMPRESS-Norway
Roche contributes eight cancer medicines to IMPRESS-Norway.
From pupil to full-time employee
Our school collaboration project has opened unexpected doors for Eivind.
New political paper: Action Plan for Clinical Studies
Norwegian government to double the number of clinical studies.
Dehns acquires Norwegian office
Dehns acquires Norwegian Intellectual Property consultancy Leogriff.
New clinical study in ovarian cancer
Ultimovacs has announced a new clinical study targeted at patients with ovarian cancer.